Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Sex Reassignment Hormone Therapy Market

U.S. Sex Reassignment Hormone Therapy Market Share

Report ID: GMI10815
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

U.S. Sex Reassignment Hormone Therapy Market Share

The market has been dominated by fierce competition. It is extremely fragmented due to the existence of both major and small firms. Major firms hold a sizable share of the market. To increase product penetration and grow their client base, major firms use a variety of techniques, including new product launches, acquisitions, partnerships, collaborations, and expansions.

U.S. Sex Reassignment Hormone Therapy Market Companies

Some of the eminent market participants operating in the U.S. sex reassignment hormone therapy industry include:

ASCEND Therapeutics US, LLC
BIOTE MEDICAL, LLC
Eli Lilly and Company
Endo International plc
Novartis AG
Noven Pharmaceuticals, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. sex reassignment hormone therapy industry size was USD 1.6 billion in 2023 and will grow at a 5.3% CAGR between 2024 and 2032 due to increasing societal acceptance and legal recognition of transgender individuals.

The hospital pharmacies segment held USD 671.1 million in 2023, driven by their pivotal role in providing comprehensive and personalized care.

East South Central U.S. sex reassignment hormone therapy industry achieved USD 417.4 million in 2023, attributed to its significant healthcare infrastructure and increasing acceptance of transgender healthcare services.

ASCEND Therapeutics US, LLC, BIOTE MEDICAL, LLC, Eli Lilly and Company, Endo International plc, Novartis AG, Noven Pharmaceuticals, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc., among others.